Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
Yoritaka Asako, Kobayashi Yasuko, Hayashi Tetsuo, Saiki Shinji, Hattori Nobutaka · Neurological Sciences · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study” is organized in H2HUBB under the research focus hydrogen inhalation research study 2021 asako. The publication is cited as Yoritaka Asako, Kobayashi Yasuko, Hayashi Tetsuo, Saiki Shinji, Hattori Nobutaka, Neurological Sciences, 2021. This randomized controlled trial examined Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study. The abstract describes Human participants; hydrogen delivered as hydrogen inhalation. The abstract reports: This pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD. This is an automated editorial draft based on the abstract and requires source review before publication.
Hydrogen inhalation research study 2021 asako overview
Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H) functions as a highly effective… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.
Study design and hydrogen intervention
Publication type: Randomized controlled trial. Evidence type: Human clinical evidence. Research model or population: Human participants. Randomized: Yes. Blinding: Double-blind. Control status: Placebo-controlled.
Delivery method: Hydrogen inhalation. Hydrogen flow rate: 2 L/min. Dose or treatment amount: 2 L.
Reported findings and scientific interpretation
For this hydrogen inhalation research study 2021 asako, the study record reports the following: The abstract reports: This pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: The abstract alone may not report all methodological limitations; full-text review is required.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.